title: Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP/ALL-2005.
authors.forename: Susana
authors.initials: S
authors.lastname: Rives
authors.forename: Mireia
authors.initials: M
authors.lastname: Camós
authors.forename: Jesús
authors.initials: J
authors.lastname: Estella
authors.forename: Pedro
authors.initials: P
authors.lastname: Gómez
authors.forename: Ma José
authors.initials: MJ
authors.lastname: Moreno
authors.forename: José Luis
authors.initials: JL
authors.lastname: Vivanco
authors.forename: Montserrat
authors.initials: M
authors.lastname: Melo
authors.forename: Rafael
authors.initials: R
authors.lastname: Fernández-Delgado
authors.forename: Amparo
authors.initials: A
authors.lastname: Verdeguer
authors.forename: Ana
authors.initials: A
authors.lastname: Fernández-Teijeiro
authors.forename: Francisco
authors.initials: F
authors.lastname: Lendínez
authors.forename: Ricardo
authors.initials: R
authors.lastname: López-Almaraz
authors.forename: José Javier
authors.initials: JJ
authors.lastname: Uriz
authors.forename: Isabel
authors.initials: I
authors.lastname: Badell
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D002648:Child; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
keywords: Philadelphia chromosome; acute lymphoblastic leukaemia; children; imatinib; tyrosine kinase inhibitor